Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 11/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211690 | 0.93 | HDAC4 (0.74) | HDAC4HDAC6HDAC1SMYD3MAPK14 | |
| SCHEMBL15726392 | 0.93 | HDAC4 (0.74) | HDAC4HDAC6HDAC1SMYD3MAPK14 | |
| SCHEMBL14645707 | 0.85 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL14645879 | 0.85 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL19701279 | 0.80 | SMYD3 (1.00) | HDAC4HDAC6SMYD3MAPK14PLK1 | |
| SCHEMBL21489870 | 0.80 | SMYD3 (1.00) | HDAC4HDAC6SMYD3MAPK14PLK1 | |
| SCHEMBL14645721 | 0.79 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL14645883 | 0.79 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL17888351 | 0.79 | NPC1 (0.60) | HDAC4HDAC6HDAC1 | |
| SCHEMBL15726370 | 0.78 | HDAC4 (0.71) | HDAC4HDAC6HDAC1SMYD3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | HDAC4, HDAC5, HDAC6 | HDAC4 1/4885HDAC6 3/4885HDAC1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.